Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
The Company granted stock options to purchase up to an aggregate of
5,500 shares of
About
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary AMPPLIFYTM
mucus-penetrating particle (MPP) Drug Delivery Technology, with an
initial focus on the treatment of eye diseases. Kala has applied the
AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol
etabonate (LE), designed for ocular applications, resulting in recently
approved INVELTYSTM for the treatment of inflammation and
pain following ocular surgery and its lead product candidate, KPI-121
0.25%, for the temporary relief of the signs and symptoms of dry eye
disease, for which a New Drug Application (NDA) was accepted for review
with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005010/en/
Source:
For Kala Pharmaceuticals, Inc.
Investors
Michael Schaffzin,
212-362-1200
michael.schaffzin@sternir.com
or
Media
Kari
Watson, 781-235-3060
kwatson@macbiocom.com